News

The trials are planned to begin in medical centers in Israel and in the US as soon as local regulatory approvals and agreements with the medical centers are

To date, the company has enrolled more than 70 subjects and participating clinical sites will be permitted to enroll additional subjects until February 10, 2009. This randomized trial

DexCom said that this revised agreement gives Animas exclusive rights to DexCom CGM technology, now and in the future, for integration into Animas insulin pumps outside the US.

This follow-on agreement, which involves technical support for the WebSDM software for use by the FDA Center for Drug Evaluation and Research review community, will help the FDA

The company expects an annualized reduction of $27 million in cash expenditures when changes are completed in the second quarter of 2009. The company remains staffed with 197

In the study, patients receiving oral Xeloda plus oxaliplatin (Xelox) lived for a median of 19 months, while patients receiving Folfox-4 lived for a median of 18.5 months.

Under the terms of the agreement, Abbott will commence a tender offer by January 26, 2009, to purchase all outstanding shares of Advanced Medical Optics (AMO) at $22

This 24-patient two-cohort, five-arm crossover study included administration of open-label oral triazolam and IV sufentanil on days one and two followed by a double-blinded, randomized dosing of a

Anthera’s fewer recurrent acute coronary events with near-term cardiovascular inflammation suppression (Francis) trial is based upon direct feedback from the FDA via the special protocol assessment procedure. The